Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy
Table 3
Ventricular function at the time of cardiotoxicity by chemotherapy agent received.
(+) Anthracycline
(−) Anthracycline
Time to toxicity in months*
5 (5)
7.5 (5.7)
Left ventricle
Baseline EF by MUGA (%)
62 ± 6
60 ± 3
Cardiotoxicity EF by MUGA (%)
48 ± 4
47 ± 4
Cardiotoxicity EF by ECHO (%)
46 ± 6
44 ± 5
Cardiotoxicity GLS
−15.5 ± 2.5
−15.7 ± 2.5
Right ventricle
Baseline EF by MUGA (%)
46 ± 4
43 ± 3
Cardiotoxicity EF by MUGA (%)
44 ± 6
40 ± 5
Cardiotoxicity FAC by ECHO (%)
42 ± 8
43 ± 5
Cardiotoxicity RVFWLS
−24.1 ± 3.9
−27.4 ± 4.6
Cardiotoxicity RVGLS
−20.4 ± 2.8
−22.8 ± 3.2
Median (IQR) onset of cardiotoxicity which occurred after initiation of TZM therapy in 21 patients; in 1 patient toxicity occurred after 3 months from the start of chemotherapy. Abbreviations as per Table 2.